Search results

Search Web pagesPDFs

Results will auto-populate based on filter selection.

Filters
Forms
News Release
Operational Policy Manual
Page
Keywords
FAQ
Forms
Provider profile
964
Found 964 result(s)
Drug benefit program value-for-money audit
Each year, we are required under the Workplace Safety and Insurance Act (WSIA) to have an external firm review the cost, efficiency, and effectiveness of one of our programs…
Drug formulary listing decision – Botulinumtoxin-A
Onabotulinumtoxin-A, incobotulinumtoxin-A, abobotulinumtoxin-A  Indication(s)  OnabotulinumtoxinA (Botox®) is indicated for the treatment of blepharospasm/VII…
Drug formulary listing decision – Buprenorphine for opioid use disorder
Buprenorphine/naloxone (SL), buprenorphine subdermal implant and buprenorphine extended-release (ER) injection Indication(s) Buprenorphine/naloxone sublingual (SL) tablet (…
Drug formulary listing decision – Calcitonin Gene-Related Peptide Monoclonal Antibodies in prevention of migraine
Indication Prevention of migraine in adults who have at least four migraine days per month. Formulary Status The WSIB Drug Advisory Committee (DAC) recommended that…
Drug formulary listing decision – Corticosteroid injections in musculoskeletal conditions
Corticosteroid injections in musculoskeletal conditions Indications/Clinical uses Treatment of acute and chronic musculoskeletal conditions including neck and upper…